Copyright Reports & Markets. All rights reserved.

Global Drugs for HAE Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Drugs for HAE Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 C1 Esterase Inhibitors
    • 1.3.3 Kallikrein Inhibitors
    • 1.3.4 Bradykinin Receptor Antagonist
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Drugs for HAE Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital and Clinic
    • 1.4.3 Pharmacy
    • 1.4.4 Other
  • 1.5 Global Drugs for HAE Market Size & Forecast
    • 1.5.1 Global Drugs for HAE Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Drugs for HAE Sales Quantity (2021-2032)
    • 1.5.3 Global Drugs for HAE Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Takeda Pharmaceuticals
    • 2.1.1 Takeda Pharmaceuticals Details
    • 2.1.2 Takeda Pharmaceuticals Major Business
    • 2.1.3 Takeda Pharmaceuticals Drugs for HAE Product and Services
    • 2.1.4 Takeda Pharmaceuticals Drugs for HAE Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Takeda Pharmaceuticals Recent Developments/Updates
  • 2.2 BioCryst Pharmaceuticals
    • 2.2.1 BioCryst Pharmaceuticals Details
    • 2.2.2 BioCryst Pharmaceuticals Major Business
    • 2.2.3 BioCryst Pharmaceuticals Drugs for HAE Product and Services
    • 2.2.4 BioCryst Pharmaceuticals Drugs for HAE Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 BioCryst Pharmaceuticals Recent Developments/Updates
  • 2.3 CSL Behring
    • 2.3.1 CSL Behring Details
    • 2.3.2 CSL Behring Major Business
    • 2.3.3 CSL Behring Drugs for HAE Product and Services
    • 2.3.4 CSL Behring Drugs for HAE Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 CSL Behring Recent Developments/Updates
  • 2.4 Pharming Healthcare
    • 2.4.1 Pharming Healthcare Details
    • 2.4.2 Pharming Healthcare Major Business
    • 2.4.3 Pharming Healthcare Drugs for HAE Product and Services
    • 2.4.4 Pharming Healthcare Drugs for HAE Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Pharming Healthcare Recent Developments/Updates

3 Competitive Environment: Drugs for HAE by Manufacturer

  • 3.1 Global Drugs for HAE Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Drugs for HAE Revenue by Manufacturer (2021-2026)
  • 3.3 Global Drugs for HAE Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Drugs for HAE by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Drugs for HAE Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Drugs for HAE Manufacturer Market Share in 2025
  • 3.5 Drugs for HAE Market: Overall Company Footprint Analysis
    • 3.5.1 Drugs for HAE Market: Region Footprint
    • 3.5.2 Drugs for HAE Market: Company Product Type Footprint
    • 3.5.3 Drugs for HAE Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Drugs for HAE Market Size by Region
    • 4.1.1 Global Drugs for HAE Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Drugs for HAE Consumption Value by Region (2021-2032)
    • 4.1.3 Global Drugs for HAE Average Price by Region (2021-2032)
  • 4.2 North America Drugs for HAE Consumption Value (2021-2032)
  • 4.3 Europe Drugs for HAE Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Drugs for HAE Consumption Value (2021-2032)
  • 4.5 South America Drugs for HAE Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Drugs for HAE Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Drugs for HAE Sales Quantity by Type (2021-2032)
  • 5.2 Global Drugs for HAE Consumption Value by Type (2021-2032)
  • 5.3 Global Drugs for HAE Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Drugs for HAE Sales Quantity by Application (2021-2032)
  • 6.2 Global Drugs for HAE Consumption Value by Application (2021-2032)
  • 6.3 Global Drugs for HAE Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Drugs for HAE Sales Quantity by Type (2021-2032)
  • 7.2 North America Drugs for HAE Sales Quantity by Application (2021-2032)
  • 7.3 North America Drugs for HAE Market Size by Country
    • 7.3.1 North America Drugs for HAE Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Drugs for HAE Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Drugs for HAE Sales Quantity by Type (2021-2032)
  • 8.2 Europe Drugs for HAE Sales Quantity by Application (2021-2032)
  • 8.3 Europe Drugs for HAE Market Size by Country
    • 8.3.1 Europe Drugs for HAE Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Drugs for HAE Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Drugs for HAE Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Drugs for HAE Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Drugs for HAE Market Size by Region
    • 9.3.1 Asia-Pacific Drugs for HAE Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Drugs for HAE Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Drugs for HAE Sales Quantity by Type (2021-2032)
  • 10.2 South America Drugs for HAE Sales Quantity by Application (2021-2032)
  • 10.3 South America Drugs for HAE Market Size by Country
    • 10.3.1 South America Drugs for HAE Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Drugs for HAE Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Drugs for HAE Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Drugs for HAE Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Drugs for HAE Market Size by Country
    • 11.3.1 Middle East & Africa Drugs for HAE Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Drugs for HAE Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Drugs for HAE Market Drivers
  • 12.2 Drugs for HAE Market Restraints
  • 12.3 Drugs for HAE Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Drugs for HAE and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Drugs for HAE
  • 13.3 Drugs for HAE Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Drugs for HAE Typical Distributors
  • 14.3 Drugs for HAE Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Drugs for HAE market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    Drugs for Hereditary Angioedema (HAE) are treatments aimed at managing and preventing the recurrent swelling attacks caused by a deficiency or dysfunction of C1 esterase inhibitor (C1-INH). Key therapies include C1-INH replacement (e.g., Berinert, Haegarda), kallikrein inhibitors (e.g., Ecallantide) to block bradykinin production, and bradykinin B2 receptor antagonists (e.g., Icatibant) to stop bradykinin from causing swelling.
    This report is a detailed and comprehensive analysis for global Drugs for HAE market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Drugs for HAE market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Drugs for HAE market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Drugs for HAE market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Drugs for HAE market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Drugs for HAE
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Drugs for HAE market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Takeda Pharmaceuticals, BioCryst Pharmaceuticals, CSL Behring, Pharming Healthcare, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Drugs for HAE market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    C1 Esterase Inhibitors
    Kallikrein Inhibitors
    Bradykinin Receptor Antagonist
    Market segment by Application
    Hospital and Clinic
    Pharmacy
    Other
    Major players covered
    Takeda Pharmaceuticals
    BioCryst Pharmaceuticals
    CSL Behring
    Pharming Healthcare
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Drugs for HAE product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Drugs for HAE, with price, sales quantity, revenue, and global market share of Drugs for HAE from 2021 to 2026.
    Chapter 3, the Drugs for HAE competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Drugs for HAE breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Drugs for HAE market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Drugs for HAE.
    Chapter 14 and 15, to describe Drugs for HAE sales channel, distributors, customers, research findings and conclusion.

    Buy now